Obesity influences the thresholds, but even in nonobese patients with dyspnea, optimal cutoffs may be lower than recommended.

Researchers from the Nagoya University Graduate School of Medicine identified an enzyme, alpha-kinase 2 (ALPK2) that is ...

A recent study published in the Clinical Research in Cardiology journal linked impaired high-density lipoprotein (HDL) ...

Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...

Research led by Professor Hai-Ling Margaret Cheng (BME) opens the door to earlier treatment and better outcomes ...

Tectonic Therapeutic is a biotechnology company focused on the development of novel therapies for cardiovascular diseases, particularly those involving pulmonary hypertension and heart failure. Its ...

TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with ...

The following is a summary of “Reduced antioxidant high-density lipoprotein function in heart failure with preserved ejection ...

The press release highlights the poor prognosis for patients with heart failure with preserved ejection fraction (HFpEF), indicating a significant unmet medical need which could suggest challenges ...

Subtle symptoms of heart disease, such as fatigue, shortness of breath, swelling in the lower legs, dizziness, and jaw pain, are often overlooked. These signs play an important role in the early ...

Tectonic Therapeutic (TECX) announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate, ...